Breaking News

Fortress Enters Devt. Deal with Alexion

Fortress-founded Caelum Biosciences to receive $60 million; Alexion has option to acquire Caelum based on Phase 2 data

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fortress Biotech-founded Caelum Biosciences has signed an agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters